Publication Of Notice Of Proposed Rulemaking To Adjust Controlled Substances Registration And Reregistration Fees
Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

United States Drug Enforcement Administration

  • Recibir Actualizaciones
  • Scam Alert
  • Menú Completo
  • English
  • Español

Main Menu

Explore DEA
  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Leadership
    • Nuestra historia
    • Divisiones Nacionales
    • DEA Museum
    • Wall of Honor
    • Contáctenos
  • Recursos
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Ley de Libertad de Información
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas

Sobrescribir enlaces de ayuda a la navegación

  • Inicio
  • Publication Of Notice Of Proposed Rulemaking To Adjust Controlled Substances Registration And Reregistration Fees

Publication Of Notice Of Proposed Rulemaking To Adjust Controlled Substances Registration And Reregistration Fees

Marzo 05, 2003
|
Share Article
|
Download Press Release
For Immediate Release
Contact: Public Information Office
Phone Number: (571) 362-1934

The Drug Enforcement Adminstration (DEA) has submitted to the Federal Register for publication a Notice of Proposed Rulemaking (NPRM) entitled "Controlled Substances Registration and Reregistration Application Fees. The DEA is publishing this NPRM to propose adjusting the current fee schedule for DEA Controlled Substances Registration to adequately recover necessary costs associated with the Diversion Control Program(DCP). The DEA published its last fee revision in 1993. Fees have remained unchanged since that time as the DEA resolved litigation regarding these fees.

Since the last published rule adjusting the fees in 1993, the DCP has experienced significant growth without any associated increase in registration fees to support the growth and increased funding needs. The DEA is required by law to collect the full costs of the DCP. The fee increases proposed in this rulemaking are required to recoup ongoing program expenses which have been affected by inflation and program activities. In addition the new fees will provide funding for congressionally approved enhancements.

The proposed fees are as follows:

Business Activity

Current Annual Cost

Proposed Annual Cost

Manufacturer

$875.00

$1,605.00

Distributor

$438.00

$804.00

Dispensing or Instructing

$70.00

$391.00/3 years

(Includes practitioner,
Hospital/clinic, retail
Pharmacy, teaching
Institiution)

 

 

Researcher - Schedule I

$70.00

$131.00

Researcher - Schedule II-V

$70.00

$131.00

Narcotic Treatment Program

$70.00

$131.00

(Including compounder)

 

 

Importer

$438.00

$804.00

Exporter

$438.00

$804.00

Analytical Laboratory

$70.00

$131.00

Disposer

$70.00

$131.00

Registrants are encouraged to read the proposal in the Federal Register publication dated February 17, 2003. Written comments must be submitted no later than 60 days after the Federal Register publication. Written comments should be submitted to the Administrator, Drug Enforcement Adminstration, Washington, DC 20537, Attention: DEA Federal Register Representative/CCR. For further information, contact Patricia M. Good, Chief Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537; Telephone (202) 307-7297.

 

Download Press Release
###
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

Christopher C. Goumenis Special Agent in Charge - Washington, DC
@DEAWashingtonDC
  • Facebook
  • X
  • Email
  • Quienes Somos
    • Sobre
    • Contáctenos
    • Museo DEA
  • Recursos
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster

United States Drug Enforcement Administration

Back
  • Quiénes somos
  • Recursos
Back
  • Sobre la DEA
  • Mission
  • Leadership
  • Nuestra historia
  • Divisiones Nacionales
  • DEA Museum
  • Wall of Honor
  • Contáctenos
Back
  • Operational Divisions
Back
  • Submit a Tip
  • Extortion Scam
  • Public Affairs
  • Social Media Directory
Back
  • Illegal Online Pharmacies
  • OD Justice
  • Fentanyl Supply Chain
  • Pill Press Resources
  • Recovery Resources
  • Together for Families
  • Ley de Libertad de Información
  • Publications
  • Galerías Multimedia
  • Programa de Asistencia a Testigos para Víctimas
Back
  • Fee Waiver
Back
  • Human Trafficking Prevention
  • Submit A Tip +
  • Get Updates
  • Scam Alert
    • English
    • Español